Russian state technology firm Rusnano is teaming up with a U.S. venture fund to invest around $760 million in a number of U.S. healthcare and pharmaceuticals firms, establish a manufacturing facility in Russia and bring new drugs to the Russian market. As part of the deal, Rusnano and life sciences technologies investor Domain Associates are planning to each invest $330 million in about 20 US-based healthcare technology companies. Rusnano, a $10 billion technology fund, and Domain, with 2.4 billion of capital under management, will also fund a pharmaceutical and medical device manufacturing facility in Russia.
